In yesterday’s Wall Street session, Moderna Inc (NASDAQ:MRNA) shares traded at $44.44, up 3.49% from the previous session.
MRNA stock price is now -12.36% away from the 50-day moving average and -52.74% away from the 200-day moving average. The market capitalization of the company currently stands at $17.70B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $42, Berenberg recently initiated with Hold rating for Moderna Inc (NASDAQ: MRNA). On November 18, 2024, HSBC Securities Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $58, while ‘Wolfe Research’ rates the stock as ‘Underperform’
In other news, Klinger Shannon Thyme, Chief Legal Officer sold 112 shares of the company’s stock on Dec 03 ’24. The stock was sold for $4,849 at an average price of $43.30. Upon completion of the transaction, the Chief Legal Officer now directly owns 19,837 shares in the company, valued at $0.88 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 03 ’24, President Hoge Stephen sold 314 shares of the business’s stock. A total of $13,595 was realized by selling the stock at an average price of $43.30. This leaves the insider owning 1,443,904 shares of the company worth $64.17 million. A total of 10.83% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $35.80 and a high of $170.47. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 4.39, and a quick ratio of 4.20. The fifty day moving average price for MRNA is $50.71 and a two-hundred day moving average price translates $94.04077 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2024-09-30. The net profit margin was -43.84% and return on equity was -17.52% for MRNA. The company reported revenue of $1.86 billion for the quarter, compared to $1.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.69 percent.
